激素洗脱支架在内镜鼻窦手术后慢性鼻窦炎管理中的疗效:更新荟萃分析
该荟萃分析系统检索1985至2018年PubMed文献,纳入7项行业资助研究、共444个激素洗脱支架(SES)鼻窦与444个对照鼻窦,评估SES对鼻内镜鼻窦手术(ESS)后结局的影响。结果显示SES可降低术后干预、手术及口服激素需求,并改善额窦口通畅性、减少粘连和息肉复发。
要点
- SES降低ESS后需干预、手术及口服激素的几率。
- SES提高额窦口通畅率,减少中重度粘连和息肉评分增加。
- 纳入研究均为行业资助,需独立研究验证长期疗效。
核心结论
- SES可改善ESS后结局,减少术后干预率和复发性息肉病及炎症,并促进额窦口通畅。
- 所有纳入分析的研究均为行业资助,无法排除发表偏倚。
- 需要未来独立、非资助的研究进一步评估SES的长期疗效。
研究设计与样本
- 系统文献检索PubMed 1985年至2018年发表的文献。
- 纳入7项行业资助研究,共444个SES鼻窦和444个对照鼻窦。
- 结局变量在干预后平均30天报告。
主要发现
- 术后需干预的集合OR为0.45(95%CI 0.33-0.62;p<0.001)。
- 术后需手术的集合OR为0.30(95%CI 0.18-0.52;p<0.001)。
- 术后需口服激素的集合OR为0.58(95%CI 0.40-0.84;p=0.004)。
- 额窦口通畅的集合OR为2.53(95%CI 1.61-3.97;p<0.001)。
- 中重度粘连/瘢痕的集合OR为0.28(95%CI 0.13-0.59;p<0.001);息肉评分增加的集合OR为0.42(95%CI 0.25-0.74;p=0.002)。
关键数值与推荐
- 额窦口/筛窦炎症集合均数差为-10.86 mm(p<0.001)。
- 额窦口直径集合均数差为+1.34 mm(p<0.001)。
临床怎么用
- 对于ESS术后慢性鼻窦炎患者,SES可能减少术后干预、手术及口服激素需求。
- SES可能有助于维持额窦口通畅并减少粘连和息肉复发。
- 临床决策时应考虑证据均来自行业资助研究,需谨慎解读。
局限性
- 所有纳入研究均为行业资助。
- 无法排除发表偏倚。
- 需要独立、非资助研究验证长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, there has been mounting evidence suggesting the efficacy of steroid-eluting stents (SES) for management of chronic rhinosinusitis after endoscopic sinus surgery (ESS). This meta-analysis serves to evaluate the efficacy of SES in improving postoperative outcomes after ESS. METHODS: A systematic literature search was performed of PubMed for articles published between 1985 and 2018. The outcome variables were reported at, on average, 30 days postintervention. RESULTS: Seven of the 76 published studies, all of which were industry-sponsored, were included for a collective cohort of 444 SES and 444 control sinuses. In patients who received SES vs controls, collective odds ratios (ORs) for postoperative need for intervention, surgery, and oral steroid were 0.45 (95% confidence interval [CI], 0.33-0.62; p < 0.001), 0.30 (95% CI, 0.18-0.52; p < 0.001), and 0.58 (95% CI, 0.40-0.84; p = 0.004), respectively. In addition, collective ORs for frontal sinus ostia (FSO) patency, moderate-to-severe adhesion/scarring, and increase in polyp score were 2.53 (95% CI, 1.61-3.97; p < 0.001), 0.28 (95% CI, 0.13-0.59; p < 0.001), and 0.42 (95% CI, 0.25-0.74; p = 0.002), respectively. Collective mean differences for FSO/ethmoid inflammation and FSO diameter were -10.86 mm (p < 0.001) and +1.34 mm (p < 0.001), respectively. CONCLUSION: Aggregate evidence suggests that SES can improve ESS outcomes by reducing rates of postoperative intervention and recurrent polyposis and inflammation, while promoting FSO patency. All included and analyzed studies were industry-sponsored and ruling-out publication bias was not possible. Future independent and nonsponsored studies to further evaluate SES's long-term efficacy are warranted.
引用
- Goshtasbi K, Abouzari M, Abiri A, et al. Efficacy of steroid-eluting stents in management of chronic rhinosinusitis after endoscopic sinus surgery: updated meta-analysis. Int Forum Allergy Rhinol. 2019. PMID: 31539461. doi:10.1002/alr.22443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。